CAS No.
1234423-95-0(Unlabeled)
Smiles
ClC1=C(C2)C([C@H](C3=CC([S](NCCOCCOCCNC(NC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])NC(NCCOCCOCCN[S](=O)(C4=CC([C@H](C5)C6=CC(Cl)=CC(Cl)=C6CN5C)=CC=C4)=O)=O)=O)(=O)=O)=CC=C3)CN2C)=CC(Cl)=C1
Storage Condition
Refer MSDS for complete information
IUPAC Name
(S)-N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl-12,12,13,13,14,14,15,15-d8)bis(3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide)
References
"Labonte, E. D., et al.: J. Am. Soc. Nephrol. 26, 1138 (2015); Spencer, A. G. and Greasley, P. J.: Curr Opin Nephrol Hypertens 24, 410 (2015)"
Synonyms
(S)-N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl-12,12,13,13,14,14,15,15-d8)bis(3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzenesulfonamide)
Application Notes
"17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."
Hazard Compound
Refer MSDS for complete information
"17-[[[3-[(4S)-6,8-Dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-12,15-dioxa-2,7,9-triazaheptadecanamide-d8 (deuterium labeled) is an inhibitor of sodium/hydrogen exchanger isoform 3 (NHE3), which is a major absorptive sodium transporter. It has therapeutic potential for lowering gastrointestinal sodium absorption and improving fluid overload-related symptoms, such as hypertension and proteinuria, in patients with CKD."
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
